#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute myeloid leukaemia (in remission) Myotonic dystrophy Hyperinsulinaemic hypoglycaemia Marginal zone lymphoma recurrent Cystic fibrosis lung Toxic epidermal necrolysis Pleomorphic leiomyosarcoma Glomerulonephritis chronic Arrhythmia Albright's disease Oropharyngeal squamous cell carcinoma Small cell lung cancer Neuromyelitis optica spectrum disorder Craniopharyngioma Heart disease congenital More trials…

    Learn about Rare Diseases

    Cytokine release syndrome – Trials in Disease Mucopolysaccharidosis – Trials in Disease Congenital nephrogenic diabetes insipidus – Diagnostics Aicardi-Goutieres syndrome – Basic Information Atypical haemolytic uraemic syndrome – Life with Disease Leiomyosarcoma recurrent – Treatment Leiomyosarcoma – Diagnostics Lymphangiosarcoma – Life with Disease Combined immunodeficiency – Basic Information Optic glioma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pf-06480605 Senicapoc AGANIRSEN Safinamide Pyrazinamide Ampreloxetine Atogepant SGN-ALPV Betaxolol Esketamine Gad20-209-Fsp-A2 TAGRAXOFUSP TUVATEXIB 1,3-BUTYLENE GLYCOL Danicamtiv Tegoprubart HEMOPEXIN, HUMAN Lovastatin Nimorazole Img-007 More therapies…

    Learn about Your Condition

    Food allergy Hypochondroplasia Psychogenic seizure Caesarean section Endometrial cancer recurrent Lung cancer metastatic Barrett's oesophagus Pancreatic carcinoma Pharyngeal cancer stage I Metastasis Suicidal ideation Langerhans' cell histiocytosis Cardiac ventricular thrombosis Incontinence Ovarian cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Jules Bordet

Institut Jules Bordet

Mijlenmeersstraat 90, Anderlecht, 1070, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Goserelin
    • Letrozole
    Austria Belgium France Germany Hungary Ireland +4

  • Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Cyclophosphamide Monohydrate
    • Diphenhydramine Hydrochloride
    • Fludarabine Phosphate
    Austria Belgium Czechia Denmark France Germany +6

  • Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Cytarabine
    Austria Belgium Czechia Germany Hungary Italy +4

  • Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    • Marginal zone lymphoma
    • Marginal zone lymphoma refractory
    Investigated Drugs:
    • Lenalidomide
    • Odronextamab
    • Rituximab
    Austria Belgium Czechia France Germany Italy +2

  • Study on the Safety and Effectiveness of BLU-222 Alone and with Drug Combination for Patients with Advanced Solid Tumors, Including Breast and Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Blu-222
    • Carboplatin
    • Fulvestrant
    Belgium France Italy Spain

  • Study Comparing Ibrutinib and Venetoclax with Chlorambucil and Obinutuzumab for First-line Treatment in Patients with Chronic Lymphocytic Leukemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Ibrutinib
    Belgium Czechia Denmark France The Netherlands Poland +2

  • Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Dexamethasone Sodium Phosphate
    • Doxorubicin Hydrochloride
    • Filgrastim
    Austria Belgium France Germany Italy The Netherlands +3

  • Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Doxorubicin
    • Paclitaxel
    • Pembrolizumab
    Belgium France Germany Hungary Ireland Poland +2

  • Study of Retifanlimab Alone and in Combination with Drug Therapy for Adults with Advanced or Metastatic Endometrial Cancer Who Have Not Responded to Platinum Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Endometrial cancer metastatic
    Investigated Drugs:
    • Human Igg1K Monoclonal Antibody Against Tim-3
    • Pemigatinib
    • Retifanlimab
    Belgium France Greece Italy

  • Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Belgium Ireland Italy The Netherlands Portugal Spain
Previous Page
1 … 17 18 19 20 21 22
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!